CompletedNCT00667121
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline
Observational studyAges 18–120United StatesDepression
Understand this study
Who was this study for?
Listed age limits: 18 years to 120 years.
- Listed locations
- Indianapolis and 5 more locationsSee all locations and recruitment
Study information
Study start dateStarted: March 16, 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 88
- Sponsor
- Mayo Clinic
- Sponsor type
- Hospital / academic medical center
- Study type
- Observational
- Intervention type
- Drug, Genetic, Other, Procedure
- Locations
- United States
- Age range
- From 18 Years to 120 Years
- Official registry ID
- NCT00667121
- Official title
Show the full official title
The Effect of Antidepressants and Gabapentin on Tamoxifen Pharmacokinetics: A Prospective Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Indianapolis · Baltimore · Ann Arbor
3 more locations
- Rochester
- Chapel Hill
- Arlington
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Mayo Clinic, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including citalopram hydrobromide, escitalopram oxalate, gabapentin, sertraline hydrochloride, tamoxifen citrate and venlafaxine.
Who was this study for?
Listed age limits: 18 years to 120 years.
